Paper Details

  1. Home
  2. Paper Details

Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies.

Author: AgajanianRichy, AllanJohn N, BranderDanielle M, BurkeJohn M, CaimiPaolo F, ChavezJulio C, CheahChan Y, ChesonBruce D, DavidsMatthew S, DerenziniEnrico, EssellJames, FenskeTimothy S, FlinnIan W, FonsecaGustavo, GhoshNilanjan, HsuYanzhi, JurczakWojciech, Knopińska-PosłusznyWanda, Lech-MarandaEwa, LeslieLori A, MiskinHari P, O'ConnorOwen A, PagelJohn M, PatelManish R, PettengellRuth, PhillipsTycel, ReevesJames A, SamaniegoFelipe, SharmanJeff P, SportelliPeter, WeissMichael S, ZinzaniPier Luigi

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Umbralisib, a dual inhibitor of PI3Kδ and CK1ε, showed a favorable long-term tolerability profile in a study of 371 patients with relapsed/refractory non-Hodgkin lymphoma. The most frequent treatment-emergent adverse events were diarrhea (52.3%), nausea (41.5%), and fatigue (31.8%). Grade 3 or higher treatment-emergent AEs occurred in 189 (50.9%) of 371 patients, and 4 patients (1.1%) died of AEs. The study supports the potential use of umbralisib for patients with lymphoid malignancies.
Paper Details　
Original Abstract of the Article :
Phosphoinositide 3-kinase-δ (PI3Kδ) inhibitors are active in lymphoid malignancies, although associated toxicities can limit their use. Umbralisib is a dual inhibitor of PI3Kδ and casein kinase-1ε (CK1ε). This study analyzed integrated comprehensive toxicity data from 4 open-label, phase 1 and 2 stu...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153017/

データ提供：米国国立医学図書館（NLM）

A New Hope for Lymphoid Malignancies: Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor

This study examines the safety and efficacy of umbralisib, a dual inhibitor of PI3Kδ and CK1ε, in treating relapsed/refractory lymphoid malignancies. The authors analyzed integrated data from four clinical trials, revealing a favorable safety profile for umbralisib and supporting its potential use for a broad range of patients with lymphoid malignancies.

Navigating the Desert of Cancer: A New Oasis of Hope

This study delves into the world of cancer treatment, exploring the potential of umbralisib, a dual PI3Kδ/CK1ε inhibitor, for treating relapsed/refractory lymphoid malignancies. Imagine the desert of cancer as a vast and unforgiving landscape. This study offers a beacon of hope, highlighting the potential of umbralisib as a new oasis of treatment options for patients battling these challenging diseases.

The Oasis of Effective Therapies: A New Pathway to Hope

This research offers a promising new avenue for treating lymphoid malignancies. The favorable safety profile of umbralisib, along with its potential efficacy, provides a glimmer of hope for patients facing these challenging diseases. It's like discovering a hidden oasis in the desert of cancer, offering a new pathway to healing and recovery.

Dr.Camel's Conclusion

This study provides a valuable assessment of the safety and efficacy of umbralisib for treating lymphoid malignancies. It's like finding a new oasis in the vast desert of cancer, offering a promising new treatment option for patients in need.

Date :
  1. Date Completed 2022-01-06
  2. Date Revised 2022-07-16
Further Info :

Pubmed ID

34547767

DOI: Digital Object Identifier

PMC9153017

Related Literature

Article Analysis
・Effects of umbralisib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.